A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007)
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Favezelimab/pembrolizumab (Primary) ; Regorafenib; Tipiracil/trifluridine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms KEYFORM-007
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 17 Mar 2025 Status changed from active, no longer recruiting to completed.
- 30 Oct 2024 Planned End Date changed from 11 Nov 2025 to 21 Feb 2025.
- 11 Jul 2024 Planned End Date changed from 31 Jul 2025 to 11 Nov 2025.